Eli Lilly (LLY) is at the center stage of the biotech market with various
developments and
analyst upgrades. The company's
stock performance has seen a surge, with potential for considerable profits and some predicting it becoming a trillion-dollar entity. Its
growth momentum builds following speculation of its stock split, similar to Netflix.
Citigroup predicts a 50% upside in Eli Lilly's stock as the company's valuation gets reassessed from a perspective of strong performance and growth. The company's oral obesity drug is projected to have underestimated sales potential, further driving the stock's price up. Eli Lilly has seen its stock rise past estimates, with sales soaring due to drugs like Zepbound and Mounjaro.
Zepbound and Mounjaro's performance has been responsible for Q3 earnings exceeding expectations. Obstacles facing the company include rival Novo Nordisk on obesity drug market share and details of rumored partnerships with Mangoceuticals getting denied. Also, it saw a dip after dropping CVS drug plan.
Eli Lilly LLY News Analytics from Tue, 16 Sep 2025 07:00:00 GMT to Sat, 15 Nov 2025 20:03:14 GMT -
Rating 8
- Innovation 9
- Information 7
- Rumor -2
